Silo Pharma, Inc.
SILO Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$1.29
KIRA · Stoqly’s AI analyst, in plain words
- Silo Pharma, Inc. had $0.1M of revenue in fiscal 2025, up 0.0% on the year before. Over five years, revenue changed +12.0% a year on average.
- Its operating margin was −5,937.2%, up 589.5 pts: of every 100 in sales, about −5,937 is left after running the business.
- Silo Pharma, Inc. lost $4.2M in fiscal 2025.
Market cap
$1.4M
P/E
0.7x
Revenue
$0.1M
Net income
−$4.2M
Free cash flow
—
Operating margin
−5,937.2%
Silo Pharma, Inc. in 30 seconds · fiscal 2025
Are sales growing?
0.0%
Only a little. Sales grew 0.0% last year.
Does it make a profit?
−5,863.7%
No. It lost money last year.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
0.7x
One share costs 0.7 times its yearly profit per share.
What Silo Pharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- Silo Pharma, Inc.
- CIK
- 0001514183
Silo Pharma, Inc. · SILO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.0M | $0.1M | $0.1M | $0.1M | $0.1M |
| Revenue growth | −107.3% | — | 0.0% | 0.0% | 0.0% |
| Net interest income | −$0.0M | — | — | — | — |
| Gross margin | −2,210.0% | 92.0% | 92.0% | 92.0% | 38.6% |
| Operating margin | 91,476.7% | −5,031.5% | −5,347.6% | −6,526.6% | −5,937.2% |
| Net income | $3.9M | −$3.9M | −$3.7M | −$4.4M | −$4.2M |
| Net margin | −130,123.3% | −5,421.1% | −5,132.7% | −6,092.8% | −5,863.7% |
| Diluted EPS | $0.04 | — | −$1.20 | −$1.19 | −$0.50 |
| Cash | |||||
| Cash from operations | −$2.3M | −$3.5M | −$3.2M | −$3.8M | −$4.7M |
| Share count change | −97.1% | 19.1% | 34.8% | 19.5% | 127.8% |
| Debt and strength | |||||
| Cash and short-term investments | $9.8M | $11.4M | $7.7M | $7.1M | $6.9M |
| Shareholders' equity | $9.1M | $10.3M | $6.2M | $5.0M | $6.3M |
| Current ratio | 21.2x | 26.5x | 9.9x | 4.3x | 11.4x |
| Interest coverage | −914.8x | −1,649.0x | −786.9x | −922.7x | −114.8x |
| Returns and quality | |||||
| Return on equity | 75.5% | −40.3% | −44.8% | −78.4% | −74.6% |
| Return on tangible equity | 27.6% | −37.8% | −59.9% | −91.7% | −69.4% |
| Piotroski F-score | 4 | 3 | 2 | 2 | 2 |
| Altman Z'' | 10.1 | 10.5 | 2.1 | −3.9 | −1.2 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Silo Pharma, Inc. · SILO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.29 a share, the company is worth $1.4M: 0.7 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001514183). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.